Welcome to our dedicated page for Arconic news (Ticker: ARNC), a resource for investors and traders seeking the latest updates and insights on Arconic stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arconic's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arconic's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Arconic Corporation (NYSE: ARNC) reported a fourth-quarter 2022 revenue of $1.9 billion, a 9% year-over-year decline, though up 2% organically. The company faced a net loss of $273 million ($2.70 per share), significantly higher than a $38 million loss in Q4 2021, partly due to a $304 million after-tax loss from divested Russian operations. For the full year, Arconic's revenue rose 19% to $9.0 billion, with a net loss of $182 million ($1.75 per share), improving from a $397 million loss in 2021. Adjusted EBITDA was $706 million for 2022. The company expects 2023 revenues between $8.0 billion and $8.5 billion.